LPTX•benzinga•
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Summary
Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga